Top-Rated StocksTop-RatedNASDAQ:IRTC iRhythm Technologies (IRTC) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free IRTC Stock Alerts $102.68 -8.20 (-7.40%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$102.55▼$113.0050-Day Range$102.09▼$120.5252-Week Range$70.24▼$134.45Volume887,487 shsAverage Volume350,414 shsMarket Capitalization$3.20 billionP/E RatioN/ADividend YieldN/APrice Target$134.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get iRhythm Technologies alerts: Email Address iRhythm Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.5% Upside$134.00 Price TargetShort InterestBearish9.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 14 Articles This WeekInsider TradingSelling Shares$4.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.14) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector5089th out of 5,424 stocksSurgical & Medical Instruments Industry541st out of 576 stocks 3.5 Analyst's Opinion Consensus RatingiRhythm Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageiRhythm Technologies has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.03% of the outstanding shares of iRhythm Technologies have been sold short.Short Interest Ratio / Days to CoveriRhythm Technologies has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in iRhythm Technologies has recently increased by 10.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldiRhythm Technologies does not currently pay a dividend.Dividend GrowthiRhythm Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRTC. Previous Next 1.1 News and Social Media Coverage News SentimentiRhythm Technologies has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for iRhythm Technologies this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for IRTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iRhythm Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,274,942.00 in company stock.Percentage Held by InsidersOnly 0.68% of the stock of iRhythm Technologies is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iRhythm Technologies are expected to grow in the coming year, from ($3.14) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iRhythm Technologies is -24.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iRhythm Technologies is -24.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiRhythm Technologies has a P/B Ratio of 14.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About iRhythm Technologies Stock (NASDAQ:IRTC)iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Read More IRTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRTC Stock News HeadlinesMay 3, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Irhythm Technologies (IRTC)May 3, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On iRhythm TechnologiesMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.May 3, 2024 | finance.yahoo.comQ1 2024 iRhythm Technologies Inc Earnings CallMay 3, 2024 | investorplace.comIRTC Stock Earnings: iRhythm Technologies Misses EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comiRhythm Technologies Announces First Quarter 2024 Financial ResultsMay 2, 2024 | finance.yahoo.comiRhythm Technologies Reports Q1 2024 Results: Revenue Surpasses Estimates Amidst Wider LossesMay 1, 2024 | markets.businessinsider.comiRhythm Technologies is about to announce its earnings — here's what Wall Street expectsMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 30, 2024 | americanbankingnews.comiRhythm Technologies, Inc. (NASDAQ:IRTC) Short Interest UpdateApril 25, 2024 | americanbankingnews.comiRhythm Technologies (IRTC) to Release Earnings on ThursdayApril 23, 2024 | finance.yahoo.comWhat Makes iRhythm Technologies (IRTC) a Lucrative Investment?April 18, 2024 | globenewswire.comiRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024April 8, 2024 | markets.businessinsider.com24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythmApril 8, 2024 | investing.comIRTC DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important April 8 Deadline in Securities Class Action “ IRTCApril 8, 2024 | businesswire.comIRTC DEADLINE TODAY: ROSEN, A RANKED AND LEADING FIRM, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important April 8 Deadline in Securities Class Action – IRTCApril 8, 2024 | prnewswire.comShareholders that lost money on iRhythm Technologies, Inc.(IRTC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreApril 6, 2024 | morningstar.comLost Money on iRhythm Technologies, Inc. (IRTC)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyApril 6, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythmApril 5, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against iRhythm Technologies, Inc. (IRTC)April 5, 2024 | finance.yahoo.comLoss-Making iRhythm Technologies, Inc. (NASDAQ:IRTC) Expected To Breakeven In The Medium-TermApril 5, 2024 | prnewswire.comInvestors who lost money on iRhythm Technologies, Inc.(IRTC) should contact The Gross Law Firm about pending Class Action - IRTCApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against iRhythm Technologies, Inc. - IRTCApril 2, 2024 | stockhouse.comINVESTOR DEADLINE MONDAY: iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - IRTCApril 2, 2024 | prnewswire.comiRhythm Technologies, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - IRTCApril 1, 2024 | prnewswire.comiRhythm Technologies, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IRTCMarch 30, 2024 | prnewswire.comIRTC DEADLINE NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important April 8 Deadline in Securities Class Action - IRTCSee More Headlines Receive IRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iRhythm Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/04/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:IRTC CUSIPN/A CIK1388658 Webwww.irhythmtech.com Phone(415) 632-5700FaxN/AEmployees2,000Year FoundedN/APrice Target and Rating Average Stock Price Target$134.00 High Stock Price Target$165.00 Low Stock Price Target$110.00 Potential Upside/Downside+31.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,410,000.00 Net Margins-25.33% Pretax Margin-24.90% Return on Equity-59.64% Return on Assets-29.94% Debt Debt-to-Equity Ratio0.17 Current Ratio2.15 Quick Ratio2.02 Sales & Book Value Annual Sales$492.68 million Price / Sales6.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.85 per share Price / Book14.99Miscellaneous Outstanding Shares31,121,000Free Float30,909,000Market Cap$3.20 billion OptionableOptionable Beta1.31 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Quentin S. Blackford (Age 45)President, CEO & Director Comp: $2.15MMr. Brice Bobzien CPA (Age 45)Chief Financial Officer Comp: $685.12kDr. Minang P. Turakhia M.D. (Age 50)M.S., Chief Medical & Scientific Officer and Executive VP of Product Innovation Comp: $1MMr. Patrick Michael Murphy J.D. (Age 45)Chief Business & Legal Officer Comp: $1.28MMr. Douglas J. Devine (Age 54)Executive Advisor Comp: $800kMr. Chad M. Patterson (Age 42)Chief Commercial Officer Comp: $771.51kMr. Marc Rosenbaum (Age 52)Senior VP of Finance & Chief Accounting Officer Mr. Mark J. Day Ph.D. (Age 53)Chief Technology Officer Comp: $718.76kMr. Daniel G. Wilson (Age 41)Executive VP of Corporate Development & Investor Relations Comp: $670.09kMs. Sumi Shrishrimal (Age 45)Executive VP & Chief Risk Officer More ExecutivesKey CompetitorsAxonicsNASDAQ:AXNXPROCEPT BioRoboticsNASDAQ:PRCTMerit Medical SystemsNASDAQ:MMSIICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMView All CompetitorsInsiders & InstitutionsMutual of America Capital Management LLCSold 1,767 shares on 5/2/2024Ownership: 0.070%Daiwa Securities Group Inc.Bought 16,600 shares on 5/2/2024Ownership: 0.053%Mirae Asset Global Investments Co. Ltd.Bought 5,276 shares on 5/1/2024Ownership: 0.251%BNP Paribas Financial MarketsBought 1,358 shares on 5/1/2024Ownership: 0.052%Capstone Investment Advisors LLCBought 9,289 shares on 5/1/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions IRTC Stock Analysis - Frequently Asked Questions Should I buy or sell iRhythm Technologies stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IRTC shares. View IRTC analyst ratings or view top-rated stocks. What is iRhythm Technologies' stock price target for 2024? 7 Wall Street research analysts have issued 12 month target prices for iRhythm Technologies' shares. Their IRTC share price targets range from $110.00 to $165.00. On average, they predict the company's stock price to reach $134.00 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price. View analysts price targets for IRTC or view top-rated stocks among Wall Street analysts. How have IRTC shares performed in 2024? iRhythm Technologies' stock was trading at $107.04 at the beginning of 2024. Since then, IRTC stock has decreased by 4.1% and is now trading at $102.68. View the best growth stocks for 2024 here. Are investors shorting iRhythm Technologies? iRhythm Technologies saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,810,000 shares, an increase of 10.2% from the March 31st total of 2,550,000 shares. Based on an average trading volume of 440,700 shares, the days-to-cover ratio is presently 6.4 days. View iRhythm Technologies' Short Interest. When is iRhythm Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our IRTC earnings forecast. How were iRhythm Technologies' earnings last quarter? iRhythm Technologies, Inc. (NASDAQ:IRTC) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.66. The firm had revenue of $132.51 million for the quarter, compared to analyst estimates of $131.14 million. iRhythm Technologies had a negative net margin of 25.33% and a negative trailing twelve-month return on equity of 59.64%. What ETFs hold iRhythm Technologies' stock? ETFs with the largest weight of iRhythm Technologies (NASDAQ:IRTC) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Robotics & Automation ETF (ROBO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV) and Alger Mid Cap 40 ETF (FRTY). What guidance has iRhythm Technologies issued on next quarter's earnings? iRhythm Technologies issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $578.0 million-$588.0 million, compared to the consensus revenue estimate of $580.8 million. What is Kevin M. King's approval rating as iRhythm Technologies' CEO? 20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among the company's employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of iRhythm Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA). When did iRhythm Technologies IPO? iRhythm Technologies (IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are iRhythm Technologies' major shareholders? iRhythm Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.33%), Allspring Global Investments Holdings LLC (1.33%), WCM Investment Management LLC (0.44%), Mirae Asset Global Investments Co. Ltd. (0.25%), Peregrine Capital Management LLC (0.22%) and Principal Financial Group Inc. (0.20%). Insiders that own company stock include Daniel G Wilson, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Merz Cathleen Noel Bairey, Patrick Michael Murphy and Quentin S Blackford. View institutional ownership trends. How do I buy shares of iRhythm Technologies? Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRTC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRhythm Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.